欧洲移民传染病筛查方法的有效性如何?一项系统综述
该研究遵循PRISMA指南检索Embase、PubMed、PsychINFO、Cochrane图书馆和Web of Science(1989年至2015年7月1日,2018年1月1日更新),纳入47项来自十个欧洲国家、涵盖248 402名移民的研究。多数欧洲国家仅针对单一疾病(主要为活动性或潜伏性结核)筛查移民,且重点针对寻求庇护者和难民,移民筛查覆盖率低(39.29% [14.53-92.50]),筛查中发现感染的比例为3.74%(范围0.00-95.16)。
要点
- 多数欧洲国家仅针对单一疾病筛查移民,主要为活动性或潜伏性结核,重点针对寻求庇护者和难民。
- 移民筛查接受率高(中位数79.50% [18.62-100.00]),基层卫生机构接受率达96.77% [76.00-100.00]。
- 移民筛查覆盖率低(39.29% [14.53-92.50]),成本效果数据稀缺但提示中等至高成本效果。
核心结论
- 欧洲国家采用多种方法筛查移民传染病,但范围限于单一疾病和窄移民亚群,覆盖率低。
- 须更重视发展创新且可持续的策略以促进筛查和治疗完成并改善健康结局,涵盖多种关键感染并考虑更广泛高危移民群体。
- 政策制定者和研究者需确保从长期视角改善移民融入接收国卫生系统过程中的健康结局。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索Embase、PubMed、PsychINFO、Cochrane图书馆和Web of Science(1989年至2015年7月1日,2018年1月1日更新),无语言限制,并系统联系欧盟专家获取灰色文献。
- 纳入标准为评估欧盟或欧洲经济区国家移民(外国出生)人群任何传染病筛查干预的原始研究。
- 共纳入47项研究,来自十个欧洲国家(比利时、丹麦、法国、意大利、荷兰、挪威、西班牙、瑞典、瑞士和英国),涵盖248 402名移民。
主要发现
- 移民中检出感染的比例为3.74%(范围0.00-95.16)。
- 潜伏性结核在所有感染中患病率最高(中位数15.02% [0.35-31.81])。
- 移民筛查接受率高(中位数79.50% [18.62-100.00]),基层卫生机构接受率为96.77% [76.00-100.00]。
- 24.62%(0.12-78.99)的移民未完成筛查且未做出最终诊断。
- 合并数据显示移民治疗完成率高(83.79%,范围0.00-100.00),但该结局数据高度异质性;仅54.45%(35.71-72.27)的潜伏性结核移民在筛查后最终完成治疗。
关键数值与推荐
- 主要结局为有效性指标:筛查接受率、覆盖率、检出感染和治疗结局。
- 22项研究报告了其他感染(包括HIV和乙型及丙型肝炎)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 治疗完成率数据高度异质性,掩盖了研究与感染之间的重要差异。
- 成本效果数据稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rates of migration to Europe, and within Europe, have increased in recent years, with considerable implications for health systems. Migrants in Europe face a disproportionate burden of tuberculosis, HIV, and hepatitis B and C, yet experience a large number of barriers to accessing statutory health care on arrival. A better understanding of how to deliver effective and cost-effective screening, vaccination, and health services to this group is now crucial. We did a systematic review to document and assess the effectiveness and cost-effectiveness of approaches used for infectious diseases screening, and to explore facilitators and barriers experienced by migrants to accessing screening programmes. Following PRISMA guidelines, we searched Embase, PubMed, PsychINFO, the Cochrane Library, and Web of Science (1989 to July 1, 2015, updated on Jan 1, 2018), with no language restrictions, and systematically approached experts across the European Union (EU) for grey literature. Inclusion criteria were primary research studies assessing screening interventions for any infectious disease in the migrant (foreign-born) population residing in EU or European Economic Area (EEA) countries. Primary outcomes were the following effectiveness indicators: uptake of screening, coverage, infections detected, and treatment outcomes. Of 4112 unique records, 47 studies met our inclusion criteria, from ten European countries (Belgium, Denmark, France, Italy, the Netherlands, Norway, Spain, Sweden, Switzerland, and the UK) encompassing 248 402 migrants. We found that most European countries screening migrants focus on single diseases only-predominantly active or latent tuberculosis infection-and specifically target asylum seekers and refugees, with 22 studies reporting on other infections (including HIV and hepatitis B and C). An infection was detected in 3·74% (range 0·00-95·16) of migrants. Latent tuberculosis had the highest prevalence across all infections (median 15·02% [0·35-31·81]). Uptake of screening by migrants was high (median 79·50% [18·62-100·00]), particularly in primary health-care settings (uptake 96·77% [76·00-100·00]). However, in 24·62% (0·12-78·99) of migrants screening was not completed and a final diagnosis was not made. Pooled data highlight high treatment completion in migrants (83·79%, range 0·00-100·00), yet data were highly heterogeneous for this outcome, masking important disparities between studies and infections, with only 54·45% (35·71-72·27) of migrants with latent tuberculosis ultimately completing treatment after screening. Coverage of the migrant population in Europe is low (39·29% [14·53-92·50]). Data on cost-effectiveness were scarce, but suggest moderate to high cost-effectiveness of migrant screening programmes depending on migrant group and disease targeted. European countries have adopted a variety of approaches to screening migrants for infections; however, these are limited in scope to single diseases and a narrow subset of migrants, with low coverage. More emphasis must be placed on developing innovative and sustainable strategies to facilitate screening and treatment completion and improve health outcomes, encompassing multiple key infections with consideration given to a wider group of high-risk migrants. Policy makers and researchers involved with global migration need to ensure a longer-term view on improving health outcomes in migrant populations as they integrate into health systems in host countries.
引用
- Seedat F, Hargreaves S, Nellums LB, et al. How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis. 2018. PMID: 29778396. doi:10.1016/S1473-3099(18)30117-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。